Now available

The first Medicare-reimbursed MRD
assay for patients with DLBCL,
available as a CLIA-validated LDT.

$0 cost for Medicare patients—and with
no frequency restrictions.


Case Studies and Insights

clonoSEQ® in real-world clinical practice

Adaptive has collected a trove of resources from leading experts to support practices’ efforts to integrate clonoSEQ NGS MRD into routine clinical practice

Select from the options below to view resources




This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

Adaptive Biotechnologies does not recommend or endorse any particular course of treatment.